MDWD (MediWound) Cyclically Adjusted Revenue per Share: $4.01 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDWD MediWound Ltd MDWD
58 GF Score
Price $13.16
GF Value $10.48
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is MediWound Cyclically Adjusted Revenue per Share?

MediWound MDWD -3.53% 58 Cyclically Adjusted Revenue per Share is $4.01 as of Jun. 2026. GuruFocus rates MDWD with a GF Score™ of 58/100 and a GF Value™ of $10.48 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

MediWound's adjusted revenue per share for the three months ended in Jun. 2026 was $0.234. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.01 for the trailing ten years ended in Jun. 2026.

During the past 12 months, MediWound's average Cyclically Adjusted Revenue Growth Rate was 5.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of MediWound was 4.50% per year. The lowest was 4.50% per year. And the median was 4.50% per year.

As of today (2026-08-20), MediWound's current stock price is $13.16. MediWound's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $4.01. MediWound's Cyclically Adjusted PS Ratio of today is 3.28.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MediWound was 5.96. The lowest was 2.11. And the median was 4.32.


MediWound  (NAS:MDWD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

MediWound's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=13.16/4.01
=3.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MediWound was 5.96. The lowest was 2.11. And the median was 4.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


MediWound Cyclically Adjusted Revenue per Share Related Terms


MediWound Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for MediWound's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediWound Cyclically Adjusted Revenue per Share Chart

MediWound Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 3.40 3.37 3.66 3.88

MediWound Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.82 3.89 3.88 3.96 4.01

MDWD vs WHWK, IMUX, IVVD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, MediWound's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MediWound Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MediWound's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MediWound's Cyclically Adjusted PS Ratio falls into.


MDWD
58GF Score
MediWound Ltd MDWD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediWound Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MediWound's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.234/333.9520*333.9520
=0.234

Current CPI (Jun. 2026) = 333.9520.

MediWound Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.166 241.428 0.230
201612 0.138 241.432 0.191
201703 0.172 243.801 0.236
201706 0.219 244.955 0.299
201709 0.231 246.819 0.313
201712 0.137 246.524 0.186
201803 0.135 249.554 0.181
201806 0.267 251.989 0.354
201809 0.221 252.439 0.292
201812 0.255 251.233 0.339
201903 0.119 254.202 0.156
201906 5.343 256.143 6.966
201909 1.324 256.759 1.722
201912 1.401 256.974 1.821
202003 1.142 258.115 1.478
202006 1.001 257.797 1.297
202009 1.706 260.280 2.189
202012 1.724 260.474 2.210
202103 1.503 264.877 1.895
202106 1.556 271.696 1.913
202109 1.637 274.310 1.993
202112 1.409 278.802 1.688
202203 1.074 287.504 1.248
202206 0.986 296.311 1.111
202209 1.213 296.808 1.365
202212 1.841 296.797 2.071
202303 0.453 301.836 0.501
202306 0.518 305.109 0.567
202309 0.518 307.789 0.562
202312 0.579 306.746 0.630
202403 0.538 312.332 0.575
202406 0.546 314.175 0.580
202409 0.414 315.301 0.438
202412 0.541 315.605 0.572
202503 0.366 319.799 0.382
202506 0.527 322.561 0.546
202509 0.493 324.800 0.507
202512 0.145 324.054 0.149
202603 0.115 330.213 0.116
202606 0.234 333.952 0.234

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $4.01 mean?
MediWound (MDWD) has a Cyclically Adjusted Revenue per Share of $4.01 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MediWound and its competitors.
Is MediWound's Cyclically Adjusted Revenue per Share too high?
MediWound's current Cyclically Adjusted Revenue per Share is $4.01. Overall, MediWound has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's Cyclically Adjusted Revenue per Share compare to WHWK and IMUX?
MediWound's Cyclically Adjusted Revenue per Share of $4.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MediWound and its competitors. MediWound's current Cyclically Adjusted Revenue per Share is $4.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.48, compared to a current price of $13.16 — trading 25.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $4.01. MediWound's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For MediWound (MDWD), the current Cyclically Adjusted Revenue per Share is $4.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MediWound (MDWD) Overvalued in 2026?

Based on GuruFocus' analysis, MediWound stock appears to be overvalued. The current stock price of $13.16 is trading 25.6% above its estimated GF Value™ of $10.48. GuruFocus considers MediWound to be Modestly Overvalued.

Key valuation signals for MDWD:

  • Cyclically Adjusted Revenue per Share: $4.01
  • GF Value™: $10.48 vs. price of $13.16 (25.6% above fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MediWound Business Description

Other Exchanges M8W:Germany
Address 42 Hayarkon Street, Yavne, ISR, 8122745
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
58GF Score

Get the complete analysis for MDWD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.16
Price
$10.48
GF Value